| Regulatory status | FDA-APPROVED The medicine is FDA-approved; this vial is sold strictly as a research chemical. |
|---|---|
| Mechanism | GLP-1 receptor agonist |
| Developer | Novo Nordisk |
| Form | Lyophilized powder · 5mg, 10mg, 20mg, 50mg |
| CAS | 910463-68-2 |
| Purity docs | Batch-matched COA available on request — ask us. |
| Ships from | Ontario, Canada |
| Intended use | Laboratory research only. Not for human consumption. |
Semaglutide is the molecule that proved the incretin class at scale. In the STEP program, once-weekly semaglutide produced sustained, clinically meaningful weight reduction with a safety profile characterized across tens of thousands of trial participants. For any metabolic research program, it is the benchmark everything else is measured against.
Lyophilized vials: keep sealed, dry, and away from light and heat. Refrigeration at 2–8°C is the best default; −20°C for long-term storage. After reconstitution: refrigerate at 2–8°C and use promptly — no beyond-use date is validated.
The reference GLP-1. The most studied weight-management peptide in existence.
New here? Read the beginner's guide →
$15 flat shipping Canada-wide · free over $200
The active ingredient in Mounjaro and Zepbound — the newer, stronger once-weekly weight-loss medicine.
Dual GIP / GLP-1 receptor agonist
A once-weekly weight-loss medicine already approved in China — still experimental in Canada and the US.
Dual GLP-1 / glucagon receptor agonist
An experimental medicine that works three ways at once — in late-stage testing, not approved anywhere yet.
Triple GIP / GLP-1 / glucagon receptor agonist
